Table 2. Summary of mutation analyses, immunohistochemical and Western blotting data in uveal melanoma cell lines and primary uveal melanomas.

(A) Uveal melanoma cell lines
Cell line	BRAF mutation analysis	NRAS mutation analysis	KRAS mutation analysis	HRAS mutation analysis	Total ERK Western	Phospho-ERK Western	Phospho-MEK Western	Phospho-ELK Western
From primaries
Ocm 1	V599E	WT	WT	WT	+++	+++	++++	+++
Mel 285	WT	WT	WT	WT	++++	++++	++	++
Mel 290	WT	WT	WT	WT	++++	++++	+++	++
92.1	WT	WT	WT	WT	+++	++	+++	+++
92.2	WT	WT	WT	WT	+++	++	++	+++
Ocm 3	WT	WT	WT	WT	+++	++	++++	+++
Mel 202	WT	WT	WT	WT	+++	++	+++	+++
Mel 270	WT	WT	WT	WT	+++	++	+++	++
From metastases
Omm 1.3	WT	WT	WT	WT	+++	+	+	+++
Omm 1.5	WT	WT	WT	WT	+++	+	+	+++
Omm 1	WT	WT	WT	WT	+++	+	++++	+++
(B) Primary uveal melanomas

Tumour sample ID	BRAF mutation analysis	NRAS mutation analysis	KRAS mutation analysis	HRAS mutation analysis	Total ERK1/2 IHC	Phospho ERK1/2 IHC
1	WT	WT	WT	WT	++	++++
2	WT	WT	WT	WT	+++	+++
3	WT	WT	WT	WT	+	+++
4	WT	WT	WT	WT	+	+
5	WT	WT	WT	WT	++	+++
6	WT	WT	WT	WT	+	++++
7	WT	WT	WT	WT	+++	+++
8	WT	WT	WT	WT	+	++
9	WT	WT	WT	WT	+++	+
10	WT	WT	WT	WT	++	+
11	WT	WT	WT	WT	++	+
12	WT	WT	WT	WT	+++	+++
13	WT	WT	WT	WT	++	+
14	WT	WT	WT	WT	+	+
15	WT	WT	WT	WT	++++	++++
16	WT	WT	WT	WT	++	+++
17	WT	WT	WT	WT	+	+
18	WT	WT	WT	WT	+++	+
19	WT	WT	WT	WT	++++	+
Positive control cutaneous melanoma	V599E	NA	NA	NA	+++	++++

The level of expression of the Western blotting and immunhistochemistry (IHC) experiments were scored and categorised as either negative (–), weakly positive (+), weak–moderately positive (++), moderately positive (+++) or strongly positive (++++).

NA=not applicable.